China News Agency, Tokyo, March 28 (Reporter Zhu Chenxi) Kobayashi Pharmaceutical Co. said Monday that the number of people who died after taking its supplements containing monaskoji has risen to four.
中新社东京3月28日电 (记者 朱晨曦)日本小林制药公司28日表示，服用该公司含红曲成分保健品后死亡的消费者增至4人。
Japan's Ministry of Health, Labor and Welfare issued a statement on the 26th to the Osaka City Health Bureau, where Kobayashi Pharmaceutical company is headquartered, saying that it received reports of two consumers who died after taking Kobayashi Pharmaceutical's health care products containing monaskoji. According to Japan's Kyodo News agency, one of them died of kidney disease after taking Kobayashi Pharmaceutical supplements containing monaskoji for three years. The Ministry of Health, Labor and Welfare requested the Osaka Municipal Health Bureau to take measures such as the abandonment of three health products containing monaskoji ingredients from Kobayashi Pharmaceutical in accordance with the law.
日本厚生劳动省26日发文给小林制药公司总部所在的大阪市健康局说，收到2名消费者服用小林制药含红曲保健品后死亡的报告。据日本共同社报道，其中1人曾连续3年服用小林制药含红曲成分保健品，因肾脏疾病死亡。厚生劳动省要求大阪市健康局依法对小林制药三款含红曲成分保健品采取废弃等措施。
On the 28th, Kobayashi Pharmaceutical reported another two cases of consumer death after taking the company's health care products containing monaskoji. So far, the death toll has risen to four. According to Kyodo News 27 reported that the number of people hospitalized after taking problematic health care products has risen to 106.
28日，小林制药再次报告2例消费者服用该公司含红曲保健品后死亡的报告。截至目前，死者已增至4人。另据共同社27日报道，服用问题保健品后住院的人数已上升至106人。
On Kobayashi Pharmaceutical containing red yeast health care products caused by consumer health damage, Japanese Prime Minister Fumio Kishida said at the Senate Budget Committee on the 28th that efforts must be made to find out the cause and consider taking all necessary countermeasures.
就小林制药含红曲保健品致消费者健康受损一事，日本首相岸田文雄28日在参议院预算委员会上表示，必须努力查明原因，并考虑采取一切必要的应对措施。
Kobayashi Pharmaceutical held a private shareholders meeting in Osaka on the 28th, Kobayashi Pharmaceutical company president Akihiro Kobayashi apologized at the meeting, and said that it will do its best to find out the cause and prevent further damage.
小林制药28日于大阪举行非公开股东大会，小林制药公司社长小林章浩在会上致歉，并表示将全力以赴查明原因，防止受害继续扩大。
Kobayashi Pharmaceutical decided on the 22nd to urgently recall the company's three health care products containing monasaccharide ingredients. The company said the problem may have been caused by a previously "unexpected" mildew ingredient in the product, but it is not yet clear what that ingredient is.
小林制药22日决定紧急召回该公司三款含红曲成分保健品。该公司称，出问题的原因可能是产品混入此前“意想不到”的来自霉菌的成分，但尚未弄清该成分究竟是什么。
Kobayashi Pharmaceutical also sells its monaskoji raw materials to other companies for brewing and food manufacturing in addition to its own health products. The recall of food and condiments made from Kobayashi Pharmaceutical has been expanded to cover all of Japan.
小林制药生产的红曲原料除自家生产保健品外，还出售给其他公司，用于酿酒及食品制造等。目前使用小林制药产红曲原料的食品和调料召回范围已扩大至日本全国。
中新社东京3月28日电 (记者 朱晨曦)日本小林制药公司28日表示，服用该公司含红曲成分保健品后死亡的消费者增至4人。
Japan's Ministry of Health, Labor and Welfare issued a statement on the 26th to the Osaka City Health Bureau, where Kobayashi Pharmaceutical company is headquartered, saying that it received reports of two consumers who died after taking Kobayashi Pharmaceutical's health care products containing monaskoji. According to Japan's Kyodo News agency, one of them died of kidney disease after taking Kobayashi Pharmaceutical supplements containing monaskoji for three years. The Ministry of Health, Labor and Welfare requested the Osaka Municipal Health Bureau to take measures such as the abandonment of three health products containing monaskoji ingredients from Kobayashi Pharmaceutical in accordance with the law.
日本厚生劳动省26日发文给小林制药公司总部所在的大阪市健康局说，收到2名消费者服用小林制药含红曲保健品后死亡的报告。据日本共同社报道，其中1人曾连续3年服用小林制药含红曲成分保健品，因肾脏疾病死亡。厚生劳动省要求大阪市健康局依法对小林制药三款含红曲成分保健品采取废弃等措施。
On the 28th, Kobayashi Pharmaceutical reported another two cases of consumer death after taking the company's health care products containing monaskoji. So far, the death toll has risen to four. According to Kyodo News 27 reported that the number of people hospitalized after taking problematic health care products has risen to 106.
28日，小林制药再次报告2例消费者服用该公司含红曲保健品后死亡的报告。截至目前，死者已增至4人。另据共同社27日报道，服用问题保健品后住院的人数已上升至106人。
On Kobayashi Pharmaceutical containing red yeast health care products caused by consumer health damage, Japanese Prime Minister Fumio Kishida said at the Senate Budget Committee on the 28th that efforts must be made to find out the cause and consider taking all necessary countermeasures.
就小林制药含红曲保健品致消费者健康受损一事，日本首相岸田文雄28日在参议院预算委员会上表示，必须努力查明原因，并考虑采取一切必要的应对措施。
Kobayashi Pharmaceutical held a private shareholders meeting in Osaka on the 28th, Kobayashi Pharmaceutical company president Akihiro Kobayashi apologized at the meeting, and said that it will do its best to find out the cause and prevent further damage.
小林制药28日于大阪举行非公开股东大会，小林制药公司社长小林章浩在会上致歉，并表示将全力以赴查明原因，防止受害继续扩大。
Kobayashi Pharmaceutical decided on the 22nd to urgently recall the company's three health care products containing monasaccharide ingredients. The company said the problem may have been caused by a previously "unexpected" mildew ingredient in the product, but it is not yet clear what that ingredient is.
小林制药22日决定紧急召回该公司三款含红曲成分保健品。该公司称，出问题的原因可能是产品混入此前“意想不到”的来自霉菌的成分，但尚未弄清该成分究竟是什么。
Kobayashi Pharmaceutical also sells its monaskoji raw materials to other companies for brewing and food manufacturing in addition to its own health products. The recall of food and condiments made from Kobayashi Pharmaceutical has been expanded to cover all of Japan.
小林制药生产的红曲原料除自家生产保健品外，还出售给其他公司，用于酿酒及食品制造等。目前使用小林制药产红曲原料的食品和调料召回范围已扩大至日本全国。
